## **REMARKS**

Claims 1, 7, 12, 14, and 17-20 have been amended. Claims 10, 15,16, 21, 23, and 24 have been cancelled. New claims 27-28 have been added. Therefore upon entry of this amendment, claims 1-9, 11, 12, 14, 17-20, and 25-28 will be pending.

## Drawings

The drawings were objected to by the Draftsperson in the last Office Action. Applicant accordingly submits herewith corrected formal drawings, which address the Draftsperson's concerns. Withdrawal of this objection is respectfully requested.

## Information Disclosure Statement

The Examiner indicated that the Information Disclosure Statement filed August 2, 2001, failed to comply with 37 CFR 1.97, 1.98 and MPEP § 609 because of incomplete information about references on sequence data from databases. Submitted herewith is a new Information Disclosure Statement, including a new PTO-1449 form, along with the requisite certification requirements.

## Claim Rejections

Claims 15 and 21 were rejected under 35 USC § 112, first paragraph. These claims have been cancelled, thereby rendering this rejection moot.

Claims 1-12, 14-21, and 23-26 were rejected under 35 USC § 112, second paragraph, as being indefinite because the method steps allegedly do not necessarily achieve the goal set forth in the preamble. Applicant has accordingly amended the preamble of each pending independent claim and respectfully requests that this rejection be withdrawn.

Claims 1-4, 6-8, 10-12, and 21 were rejected under 35 U.S.C. § 102(a) as being anticipated by Zhou *et al.*, *J. Cell Biology* 146:1133-146, September 6, 1999. Applicants respectfully traverse and submit herewith a Declaration under 37 C.F.R. § 1.131 swearing behind Zhou *et al.* This § 1.131 Declaration, including Exhibit A, demonstrates that the claimed invention was conceived and reduced to practice prior to the September 6, 1999, publication date

Pippig *et al.* App. No. 09/817,487

of Zhou et al. Accordingly, Applicant respectfully submits that Zhou et al. cannot properly be used as a § 102 reference, and requests that this rejection be withdrawn.

Claims 9, 14-17, 19-20, 23, and 24 were rejected under 35 U.S.C. § 103(a) as being unpatentable over Bordignon *et al.* (WO 95/06723, March 9, 1995) in view of Zhou *et al.*, *J. Cell Biology* 146:1133-146, September 6, 1999. Applicants respectfully traverse and submit that in view of the § 1.131 Declaration, the combination of Bordignon *et al.* (WO 95/06723) and Zhou *et al.* cannot properly be used to reject any of the pending claims. Applicant therefore respectfully requests that the § 103(a) rejection of these claims be withdrawn.

Claims 18 was rejected under 35 U.S.C. § 103(a) as being unpatentable over Bordignon et al. (WO 95/06723, March 9, 1995) in view of Zhou et al., J. Cell Biology 146:1133-146, September 6, 1999, as applied to claims 9, 14-17, 19-20, 23, and 24, and further in view of either Persons et al., Blood 90:1777-1786, 1997, or Hildinger et al., Gene Therapy 6:1222-1230, 1999. Applicants respectfully traverse and submit that in view of the § 1.131 Declaration, the combination of Bordignon et al. (WO 95/06723), Zhou et al., and Persons et al. or Hildinger et al., cannot properly be used to reject claim 18. Applicant therefore respectfully requests that this rejection be withdrawn.

Claims 18-20 have been amended to correct claim dependency.

No new matter has been added. If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

NOVARTIS
Corporate Intellectual Property
564 Morris Avenue
Summit, NJ 07901-1027

Telephone: 301-258-4715

Date: February 26, 2003

J. Timothy Meigs
Attorney for Applicant

Registration No. 38,241